Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.

Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.

Item

http://www.wikidata.org/entity/Q34955679

Q34955679

about

Phosphodiesterase 4-targeted treatments for autoimmune diseases The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast Relaxant and anti-inflammatory effect of two thalidomide analogs as PDE-4 inhibitors in pregnant rat uterus Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.Advances in targeting cyclic nucleotide phosphodiesterases Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors.Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.The effects of apremilast on the QTc interval in healthy male volunteers: a formal, thorough QT study.Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease Apremilast as a treatment for psoriasis.Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.Apremilast for the treatment of psoriatic arthritis.Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.Apremilast for the treatment of psoriasis.Apremilast for the treatment of psoriatic arthritis.Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others.A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Progress in Small Molecule Drug Development.Apremilast: A Review in Psoriasis and Psoriatic Arthritis.PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue.Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.1-Imidoalkylphosphonium salts with modulated Cα-P+ bond strength: synthesis and application as new active α-imidoalkylating agents.Crystal structure of an apremilast ethanol hemisolvate hemihydrate solvatomorph.Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.Apremilast Alters Behavioral Responses to Ethanol in Mice: I. Reduced Consumption and Preference.Inhibition of Uterine Contractility by Thalidomide Analogs via Phosphodiesterase-4 Inhibition and Calcium Entry Blockade.Synthesis and evaluation of thalidomide and phthalimide esters as antitumor agents.Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases

P2860

Q21245284-CDBB7115-152B-43D4-94CF-DA31A8A22933 Q26750377-0703F3A6-6FF1-42EE-9F58-355BD95A82C4 Q26781755-B598740B-A8EF-45F1-9C3C-D4C43514111F Q33899061-2B151A17-4E16-4E72-92AC-892AE5F2E8C1 Q34091087-CB0A4712-ED2E-479D-98C6-ADCCCD7A7C8C Q34139490-CDA5E4F0-2BBC-445D-AB90-CBBC95A3EDF8 Q34209887-A2131A77-77E0-4F65-B210-49A2A8941544 Q34530196-CE8E23A7-BA98-4A83-80B8-B1204E73CB4B Q36061710-4D8D0837-6A6B-4244-BA53-5C1FB7F5F68B Q36923514-8034627A-1FCC-4CB1-B801-21CCA5E3CC02 Q37104915-BCBC4092-12BF-46D7-86FF-41D313F810D0 Q37505449-FDAE4D3D-9541-48D3-924B-004B33D76C76 Q38019980-5456E2C9-1AF9-4C61-B2DF-5B4F50C5B6D2 Q38032568-6111EE62-E617-44FD-ACD9-AE74C3D60342 Q38202205-50922577-0988-438C-8B10-336E7A07A081 Q38416536-F7E825BD-A6F8-4B92-955B-F457CCD5E014 Q38561061-03778390-239F-4B0B-BDD4-E933BC994C1E Q38616811-DD4DE881-BB39-446C-97AC-F202BCD4508C Q38649220-D8BFE029-4F68-40BB-B70C-2E4A478BEBFB Q38675867-A077AEEF-5088-47D4-B7D2-7BB1766B7AE1 Q38885459-4EE04C14-15D4-4B49-8B9C-6CA2F8CC2F64 Q38974307-96D07B28-E015-4D36-911C-D29E1008C1B8 Q39141679-5E00018D-5BDD-43E6-90C2-122EE742BB26 Q39375417-408F22A7-4CAE-4E43-B8CE-91D90AACF556 Q40041736-73EB14F1-984C-4B99-B032-EF8E59A38EBE Q41334941-4CCE6486-3C64-40BF-9EBC-E9C6CBC0AEFC Q42223106-6B6EBA49-86AF-462D-AF98-F83646346158 Q42663487-6C163739-CF4D-4BCE-9194-80E1A55BDDB5 Q51749016-118EE412-A886-4079-A63C-4E29C7B92BD0 Q53009751-AD0C758E-DBB7-4887-BC42-7EF1A8AE70FE Q53839555-5544815C-0A41-4F08-8F0C-C5204BC5E905 Q58606499-A9FA4963-9F77-45DC-9624-6F5BCAE92B3A

P2860

Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.

Item

http://www.wikidata.org/entity/Q34955679

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu